CN110769855A - 用于治疗视网膜病变的组合物和方法 - Google Patents

用于治疗视网膜病变的组合物和方法 Download PDF

Info

Publication number
CN110769855A
CN110769855A CN201880034705.1A CN201880034705A CN110769855A CN 110769855 A CN110769855 A CN 110769855A CN 201880034705 A CN201880034705 A CN 201880034705A CN 110769855 A CN110769855 A CN 110769855A
Authority
CN
China
Prior art keywords
tyrosine
methyl
methyl ester
amino
ester hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880034705.1A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文·霍夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN110769855A publication Critical patent/CN110769855A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
CN201880034705.1A 2017-04-21 2018-04-20 用于治疗视网膜病变的组合物和方法 Pending CN110769855A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488161P 2017-04-21 2017-04-21
US62/488,161 2017-04-21
PCT/US2018/028552 WO2018195411A1 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Publications (1)

Publication Number Publication Date
CN110769855A true CN110769855A (zh) 2020-02-07

Family

ID=62117055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880034705.1A Pending CN110769855A (zh) 2017-04-21 2018-04-20 用于治疗视网膜病变的组合物和方法

Country Status (11)

Country Link
US (2) US11351136B2 (cg-RX-API-DMAC7.html)
EP (1) EP3612225A1 (cg-RX-API-DMAC7.html)
JP (1) JP7171611B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190138683A (cg-RX-API-DMAC7.html)
CN (1) CN110769855A (cg-RX-API-DMAC7.html)
AU (1) AU2018254556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3060417A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992515A1 (cg-RX-API-DMAC7.html)
MX (1) MX2019012476A (cg-RX-API-DMAC7.html)
PH (1) PH12019502380A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018195411A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968785A4 (en) 2019-05-14 2023-01-11 Tyme, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390215A (zh) * 1999-09-10 2003-01-08 麦克公司 酪氨酸激酶抑制剂
CN104220057A (zh) * 2012-01-17 2014-12-17 迪美公司 药物组合物和方法
CN105848652A (zh) * 2013-10-22 2016-08-10 史蒂文·霍夫曼 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
CN106232105A (zh) * 2013-10-22 2016-12-14 迪美公司 酪氨酸衍生物以及包含酪氨酸衍生物的组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451422A1 (en) * 1990-04-13 1991-10-16 Merrell Dow Pharmaceuticals Inc. Pharmaceutically active fluoromethyltyrosine compounds
JP4758581B2 (ja) 1999-11-30 2011-08-31 アルコン,インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
NZ552816A (en) 2007-01-24 2009-05-31 Bomac Research Ltd Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof
EP2114386B9 (en) 2007-01-29 2013-09-18 Vlife Sciences Technologies Pvt Ltd. Pharmaceutical composition for treatment of diabetic complications
AU2008347005B2 (en) 2008-01-03 2013-10-03 Biomarin Pharmaceutical Inc. Pterin analog for treating BH4 responsive condition
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
JP6836991B2 (ja) 2014-12-23 2021-03-03 スティーブン・ホフマン 経皮製剤
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1390215A (zh) * 1999-09-10 2003-01-08 麦克公司 酪氨酸激酶抑制剂
CN104220057A (zh) * 2012-01-17 2014-12-17 迪美公司 药物组合物和方法
CN105848652A (zh) * 2013-10-22 2016-08-10 史蒂文·霍夫曼 用于治疗肠渗透性过高的酪氨酸羟化酶抑制剂
CN106232105A (zh) * 2013-10-22 2016-12-14 迪美公司 酪氨酸衍生物以及包含酪氨酸衍生物的组合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A.A. VUGLER ET AL: "Constant illumination causes spatially discrete dopamine depletion in the normal and degenerate retina", 《JOURNAL OF CHEMICAL NEUROANATOMY》 *
姚燕鸿 等: "抗眼底新生血管药物的研究进展", 《国际眼科杂志》 *
段辉: "《眼科临床药物手册》", 28 February 2017 *

Also Published As

Publication number Publication date
US20180303783A1 (en) 2018-10-25
US11351136B2 (en) 2022-06-07
AU2018254556A1 (en) 2019-11-14
KR20190138683A (ko) 2019-12-13
JP7171611B2 (ja) 2022-11-15
MX2019012476A (es) 2020-02-12
US20220288003A1 (en) 2022-09-15
PH12019502380A1 (en) 2020-09-14
EP3612225A1 (en) 2020-02-26
US12364676B2 (en) 2025-07-22
CA3060417A1 (en) 2018-10-25
JP2020517663A (ja) 2020-06-18
AU2018254556B2 (en) 2024-05-02
EA201992515A1 (ru) 2020-04-09
WO2018195411A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2020203101B2 (en) Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability
US10857118B2 (en) Compositions and methods for treating intestinal hyperpermeability
CN107835695A (zh) 用于治疗自闭症的组合物和方法
US12364676B2 (en) Compositions and methods for treating retinopathy
US20170151242A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis
EA046053B1 (ru) Композиции и способы для лечения ретинопатии
WO2016085981A1 (en) Method of inhibiting or treating fibrosis
AU2013270622B2 (en) Composition and method for treating or preventing skeletal muscle fibrosis
AU2018202423A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination